Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy | Zendy

Jarosław B. Ćwikła | Zendy; Lisa Bodei | Zendy; Agnieszka Kolasińska-Ćwikła | Zendy; A Sankowski | Zendy; Irvin M. Modlin | Zendy; Mark Kidd | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy

Author(s) -

Jarosław B. Ćwikła,

Lisa Bodei,

Agnieszka Kolasińska-Ćwikła,

A Sankowski,

Irvin M. Modlin,

Mark Kidd

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2792

Subject(s) - medicine , chromogranin a , prospective cohort study , somatostatin , neuroendocrine tumors , gastroenterology , lanreotide , radionuclide therapy , somatostatin receptor , octreotide , oncology , pathology , urology , nuclear medicine , immunohistochemistry , hormone , acromegaly , growth hormone

Early and precise delineation of therapeutic responses are key issues in neuroendocrine neoplasm/tumor management. Imaging is currently used but exhibits limitations in sensitivity and specificity. The utility of biomarkers is unclear. objective, setting, and design: This prospective cohort study (11 mo) sought to determine whether measurements of circulating neuroendocrine tumor transcripts (NETest) predict responses to somatostatin analogs (SSAs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research